<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00365898</url>
  </required_header>
  <id_info>
    <org_study_id>HMP3011</org_study_id>
    <nct_id>NCT00365898</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain</brief_title>
  <official_title>A Study of the Efficacy and Safety of 8 Mg Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Purdue Pharma LP</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Purdue Pharma LP</source>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the efficacy and safety of 8 mg Hydromorphone
      Hydrochloride Extended-Release.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary efficacy objective of this study is to compare the time to emergence of
      inadequate analgesia of 8 mg Hydromorphone Hydrochloride Extended-Release taken once every 24
      hours versus placebo in the treatment of patients with persistent pain who require an opioid
      medication for control of their pain.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>July 2005</start_date>
  <completion_date>July 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to emergence of inadequate analgesia. Emergence of inadequate analgesia is defined as one or more of the following: a) the subject has a rating of poor or fair on the Patient Global Assessment of Pain Medicatio</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment of Pain Medication</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Control Questionnaire</measure>
  </secondary_outcome>
  <enrollment>380</enrollment>
  <condition>Chronic Non-Malignant Pain</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydromorphone Hydrochloride Extended-Release</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  persistent, moderate-to-severe noncancer related pain requiring continuous analgesia
             for weeks to months, or longer, who are currently taking 20 to 40 mg of oxycodone or
             opioid equivalents per day for control of their persistent pain and who are willing to
             accept the possibility of receiving placebo during the Double-Blind Phase

        Exclusion Criteria:

          -  Patients already receiving opioid medication at an average total daily dose greater
             than 40 mg of oxycodone or opioid equivalents during the last week prior to study
             entry.

        Other protocol-specific exclusion/inclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arizona Research Center 2525 W. Greenway Rd. Suite 114</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc. 2147 NE Coachman Road</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LCFP, Inc. 12631 World Plaza Lane Building 54</name>
      <address>
        <city>Ft. Myers</city>
        <state>Florida</state>
        <zip>33907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmaceutical Research Associates 1395 N. Courtenay Pkwy</name>
      <address>
        <city>Merritt Island</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stedman Clinical Trials 3212 Cove Bend Drive</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research Center 1897 Palm Beach Lakes Blvd.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gold Coast Research 2965 Surrey Lane</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PharmQuest 301 E Wendover Avenue Suite 411</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hightop Medical Research Center 6103 Hamilton Anenue</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Greater Dayton 1010 Woodman Drive</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacotherapy Research Associates, Inc. 3620 Court Drive</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Pain Management-PC 1402 Ninth Ave</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>he Tipton Medical &amp; Diagnostic Center #334 Route 220</name>
      <address>
        <city>Tipton</city>
        <state>Pennsylvania</state>
        <zip>16684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Preferred Primary Care Physicians 202 Jacob Murphy Lane</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2006</study_first_submitted>
  <study_first_submitted_qc>August 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2006</study_first_posted>
  <last_update_submitted>August 16, 2006</last_update_submitted>
  <last_update_submitted_qc>August 16, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2006</last_update_posted>
  <keyword>Chronic non-malignant pain, opioid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

